17-DMAG
Hsp90 inhibitor
Product Specifications
Background
17-DMAG is a water soluble & cell-permeable analog of Geldanamycin and 17-AAG (1). It binds to the APTase site of human Hsp90a with high affinity, has cytotoxic activity against many cancer cell lines (2), and acts as angiogenesis inhibitor (3). This Hsp90 inhibitor shows promise in preclinical models. 17-DMAG has excellent bioavailability, is widely distributed to tissues, and is quantitatively metabolized much less than is 17-AAG. It clears alpha-synuclein aggregates by inducton of autophagy (4).
CAS Number
467214-20-6
Product Name Alternative
Alvespimycin, 17DMAG, 17- (dimethylaminoethylamino) -17-demethoxy-geldanamycin, 17- (dimethylaminoethylamino) -17-demethoxygeldanamycin, 17-desmethoxy-17-n, n-dimethylaminoethylamino-geldanamycin, 17-dimethylaminoethylamino-17-demethoxy-geldanamycin, 17-DMAG, 17-Dimethylaminoethylamino, 17-Demethoxygeldanamycin, [ (3R,5S,6R,7S,8E,10S,11S,12Z,14E) -21-[2- (dimethylamino) ethylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1 (21),8,12,14,18-pentaen-10-yl] carbamate
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cancer | Heat Shock | Neuroscience | Neurodegeneration | Parkinson's Disease | Synuclein
Purity
>98% (TLC) ; NMR conforms
Weight
0.001
Format
Purple Solid
Solubility
Soluble in DMSO (30 mg/ml) and ethanol (10 mg/ml)
Molecular Formula
C32H48N4O8
Molecular Weight
616.8
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Bull E.E., et al.(2004) Clin. Cancer Res. 10: 8077.
2. Gossett D.R. et al.(2005) Gynecol. Oncol. 96: 381.
3. Kaur G. et al.(2004) Clin. Cancer Res. 10: 4813. 4. RA Frake et al. (2015) J Clin Invest. 125(1): 65-74.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog